Diabetic Macular Edema
📧 Sign up to get email alerts when something new happens for Diabetic Macular Edema.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-03-22Clinical Trial Update: Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema [Phase 1, Phase 2]
Clinical trial update reports safety and bioactivity data for AXT107 in diabetic macular edema, with the study terminated.
-
CLINICAL_TRIALS trial_result · 2024-03-06Clinical Trial Update: Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed by Intraoperative OCT (the VIDEO Study): Study Protocol for a Randomized Controlled Trial [Phase 4]
A study protocol for a Phase 4 randomized controlled trial comparing vitrectomy with dexamethasone implant versus aflibercept in diabetic ma…
-
CLINICAL_TRIALS trial_result · 2024-02-06Clinical Trial Update: Bangladesh PRODUCTIVity in Eyecare Trial [NA]
Clinical trial update for the Bangladesh PRODUCTIVity in Eyecare trial; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2024-01-05Clinical Trial Update: A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema [Phase 3]
A Phase 3 study comparing the efficacy and safety of brolucizumab versus aflibercept in diabetic macular edema has completed with results po…
-
CLINICAL_TRIALS trial_result · 2023-12-18Clinical Trial Update: Evaluation of RC28-E Injection in Diabetic Macular Edema [Phase 2]
Phase 2 clinical trial update evaluating RC28-E injection for diabetic macular edema has been completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-12-14FDA Approved: EYLEA — Supplemental Application (Regeneron Pharmaceuticals, Inc.)
The FDA approved a supplemental application for EYLEA (aflibercept) from Regeneron Pharmaceuticals, Inc.
-
FDA label_change · 2023-12-14FDA Approved: EYLEA HD — Supplemental Application (Regeneron Pharmaceuticals, Inc)
FDA approved a supplemental application for EYLEA HD (aflibercept) from Regeneron, indicating a labeling change for the high-dose formulatio…
-
CLINICAL_TRIALS trial_result · 2023-12-05Clinical Trial Update: Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema [Phase 3]
A Phase 3 trial comparing CT-P42 with Eylea in diabetic macular edema has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-12-01Clinical Trial Update: A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab [Phase 2]
Phase 2 trial investigating faricimab in treatment-naïve diabetic macular edema with multimodal imaging biomarkers; study completed and resu…
-
CLINICAL_TRIALS trial_result · 2023-11-27Clinical Trial Update: A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema [Phase 2]
Phase 2 trial evaluating THR-149 for diabetic macular edema has completed.
-
CLINICAL_TRIALS trial_result · 2023-11-21Clinical Trial Update: Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease [Phase 2, Phase 3]
A Regeneron trial evaluated high-dose aflibercept for diabetic macular edema in diabetic eye disease. The Phase 2/3 study has completed, and…
-
FDA approval · 2023-10-26FDA Approved: VABYSMO — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for VABYSMO (faricimab) by Genentech, expanding its labeling/indication via supplemental approval.
-
CLINICAL_TRIALS trial_result · 2023-10-12Clinical Trial Update: Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema [Phase 2]
Phase 2 study evaluating multiple-dose safety and efficacy of LKA651 in diabetic macular edema; results have been posted.
-
CLINICAL_TRIALS trial_result · 2023-10-10Clinical Trial Update: A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe [Phase 3]
Phase 3 trial update assessing the safety of the faricimab prefilled syringe in patients with neovascular age-related macular degeneration o…
-
FDA approval · 2023-10-03FDA Approved: BYOOVIZ — Supplemental Application (BIOGEN INC.)
FDA approved Biogen's BYOOVIZ (ranibizumab-nuna) via a supplemental application, providing an additional approval for this ranibizumab biosi…
-
CLINICAL_TRIALS withdrawal · 2023-10-02Clinical Trial Update: Combined Ranibizumab and Iluvien for Diabetic Macular Oedema [Phase 2, Phase 3]
A clinical trial evaluating combined ranibizumab and Iluvien for diabetic macular edema has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2023-09-05Clinical Trial Update: Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema [Phase 3]
A Phase 3 clinical trial comparing RC28-E to aflibercept for efficacy and safety in diabetic macular edema is currently recruiting.
-
FDA approval · 2023-08-18FDA Approved: EYLEA HD — Original Application (Regeneron Pharmaceuticals, Inc)
FDA approved a high-dose formulation of EYLEA (aflibercept) under a new original application for its retinal disease indications.
-
CLINICAL_TRIALS trial_result · 2023-08-18Clinical Trial Update: A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema. [Phase 2]
Phase 2 trial update for THR-687 in diabetic macular edema was terminated; results posted in 2023.
-
FDA approval · 2023-06-16FDA Approved: BYOOVIZ — Supplemental Application (BIOGEN INC.)
FDA approved a supplemental application for BYOOVIZ (ranibizumab-nuna) from Biogen Inc.
-
CLINICAL_TRIALS trial_result · 2023-05-11Clinical Trial Update: Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME) [Phase 1, Phase 2]
Clinical trial update for SF0166 in diabetic macular edema reports completed Phase 1/2 with safety and exploratory efficacy data.
-
CLINICAL_TRIALS trial_result · 2023-03-14Clinical Trial Update: Efficacy and Safety Study of Intravitreal Triamcinolone to Treat Diffuse Diabetic Macular Edema [Phase 3]
Phase 3 trial evaluating intravitreal triamcinolone for diffuse diabetic macular edema has completed.
-
CLINICAL_TRIALS trial_result · 2023-03-07Clinical Trial Update: Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME) [Phase 3]
Phase 3 trial comparing MYL-1701P to Eylea for diabetic macular edema completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-02-27Clinical Trial Update: Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy [Phase 2]
Phase 2 trial assessing APX3330 for safety and efficacy in diabetic retinopathy and diabetic macular edema has completed.
-
CLINICAL_TRIALS trial_result · 2023-02-22Clinical Trial Update: Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections [Phase 4]
Phase 4 trial update on DEXTENZA for pain and inflammation in patients receiving intravitreal anti-VEGF injections; study terminated.